Narrative review / 2014
A commentary calls for an urgent regulatory re-evaluation of aspartame based on evidence indicating potential carcinogenic effects.
This commentary reviews the adequacy of 1970s rodent carcinogenicity bioassays submitted for aspartame's market approval alongside experimental and epidemiological data that emerged in 2005. The authors conclude that original studies by G.D. Searle and other chronic bioassays fail to provide adequate scientific support for aspartame's safety. Instead, recent life-span bioassays in rodents and a prospective epidemiological study offer consistent evidence of carcinogenic potential, prompting a call for urgent regulatory re-evaluation.
- Study type
- Narrative review / commentary
- Who was studied
- Rodent bioassays and prospective epidemiological study data
- What was measured
- Carcinogenic potential and safety of aspartame
THE PAPER
The carcinogenic effects of aspartame: The urgent need for regulatory re-evaluation.
Soffritti M, Padovani M, Tibaldi E, Falcioni L, Manservisi F, Belpoggi F. Am J Ind Med, 2014.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.